| Age at exposure, yr | Age at outcome, yr | Breast | Endometrium | Ovary | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Observed cases* | PAR†, % | EAC‡ | Observed cases* | PAR, % | EAC | Observed cases* | PAR, % | EAC | ||
| Oral contraceptives: ever use | ||||||||||
| 35-44 | 43-52 | 463 | 7.0 | 32 | 57 | -64.8 | -37 | 36 | -33.2 | -12 |
| 45-54 | 53-62 | 584 | 6.9 | 40 | 183 | -63.4 | -116 | 46 | -32.6 | -15 |
| 55-64 | 63-72 | 559 | 6.5 | 36 | 152 | -57.3 | -87 | 46 | -30.0 | -14 |
| ≥ 65 | ≥ 73 | 522 | 5.2 | 27 | 90 | -40.4 | -36 | 51 | -22.3 | -11 |
| Total | 2128 | 135 | 482 | -276 | 179 | -52 | ||||
| Hormone therapy: ever use | ||||||||||
| 35-44 | 43-52 | |||||||||
| 45-54 | 53-62 | 584 | 9.0 | 52 | 183 | -5.9 | -11 | 46 | 4.8 | 2 |
| 55-64 | 63-72 | 559 | 19.0 | 106 | 152 | -15.3 | -23 | 46 | 10.8 | 5 |
| ≥ 65 | ≥ 73 | 522 | 19.1 | 100 | 90 | -15.3 | -14 | 51 | 10.8 | 6 |
| Total | 1665 | 258 | 425 | -48 | 143 | 13 | ||||
| Hormone therapy: current use | ||||||||||
| 35-44 | 43-52 | |||||||||
| 45-54 | 53-62 | 584 | 9.3 | 54 | 183 | -4 | -7 | 46 | 6.0 | 3 |
| 55-64 | 63-72 | 559 | 15.2 | 85 | 152 | -7.3 | -11 | 46 | 10.0 | 5 |
| ≥ 65 | ≥ 73 | 522 | 11.4 | 60 | 90 | -5.1 | -5 | 51 | 7.4 | 4 |
| Total | 1665 | 199 | 425 | -23 | 143 | 12 | ||||
Note: EAC = excess attributable risk due to exposure, PAR = population attributable risk.
*The values represent the total number of cases of each cancer type diagnosed in 2012. For hormone therapy, only postmenopausal cases of cancer (cancers diagnosed at age 53 yr and older) are included.
†Represents the proportion of cancer cases attributable to oral contraceptive ever use, hormone therapy ever use or hormone therapy current use. The negative values represent preventable proportions of cancer cases owing to protective effect.
‡Represents the number of cases attributable to oral contraceptive ever use, hormone therapy ever use or hormone therapy current use. The negative values represent preventable cancer cases owing to protective effect.